Grifols (GRFS) Cash from Investing Activities Growth (1y) (2011 - 2020)
Grifols (GRFS) Cash from Investing Activities Growth (1y) (2011 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 93.92% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -1.35% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -627.53% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -38.43% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -38.14% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -46.27% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -388.99% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -46.70% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 78.10% |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 56.61% |
| Dec 31, 2019 | -157.70% |
| Mar 31, 2019 | -340.75% |
| Dec 31, 2018 | -68.90% |
| Jun 30, 2018 | -676.00% |
| Mar 31, 2018 | -93.95% |
| Dec 31, 2017 | 2,116.99% |
| Dec 31, 2016 | 90.81% |
| Sep 30, 2016 | -1,045.50% |
| Dec 31, 2015 | -1,326.81% |
| Sep 30, 2015 | -97.72% |
| Jun 30, 2015 | 127.26% |
| Mar 31, 2015 | -126.24% |
| Dec 31, 2014 | 10.07% |
| Sep 30, 2014 | 4,410.93% |
| Jun 30, 2014 | -6,268.57% |
| Mar 31, 2014 | 2,151.36% |
| Dec 31, 2013 | 52.36% |
| Sep 30, 2013 | 368.96% |
| Jun 30, 2013 | 3,273.90% |